Regulatory approval
Published by the Health Service Executive. Approved
Treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
This is written in the approval document.
Reimbursement
CDS
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HSE (1) | not BCR::ABL1 | Acute Lymphoid Leukemia | Ponatinib | |
| HSE (1) | ABL1 p.T315I, not BCR::ABL1 | Acute Lymphoid Leukemia | Ponatinib |